<DOC>
	<DOCNO>NCT02068235</DOCNO>
	<brief_summary>This study consist single-dose pilot phase randomize , two-way crossover , single-dose main phase.The aim study evaluate absolute bioavailability oral formulation ( tablet ) ponesimod compare intravenous ( i.v . ) ponesimod formulation . Three subject include pilot phase 12 subject main crossover phase .</brief_summary>
	<brief_title>Study Investigate Absolute Bioavailability Single Oral Dose Ponesimod Healthy Male Subjects</brief_title>
	<detailed_description />
	<criteria>Signed informed consent local language prior studymandated procedure . Body mass index ≥ 18 ≤ 28 kg/m^2 screening . No clinically significant finding physical examination screening . Systolic blood pressure ( SBP ) 100−145 mmHg diastolic blood pressure ( DBP ) 50−90 mmHg , measure dominant arm , 5 min supine position screen Day −1 pilot phase/ first treatment period main phase . 12lead ECG without clinically relevant abnormality screen Day −1 pilot phase / first treatment period main phase . Negative result urine drug screen screen Day −1 pilot phase / first treatment period main phase . Hematology clinical chemistry variable deviate normal range clinically relevant extent screening . Ability communicate well investigator , local language , understand comply requirement study . Known allergic reaction hypersensitivity active compound excipients drug formulation ( ) . History clinical evidence disease and/or existence surgical medical condition , might interfere absorption , distribution , metabolism , excretion study drug ( appendectomy herniotomy allow , cholecystectomy allow ) . Veins unsuitable i.v . puncture either arm ( e.g. , vein difficult locate , access , puncture vein tendency rupture puncture ) . Heart rate &lt; 50 &gt; 95 beat per minute ( bpm ) screen Day −1 pilot phase / first treatment period main phase 12lead ECG measure 5 min supine position . PR interval ( time interval begin P wave begin QRS complex ) &gt; 200 m screen Day 1 pilot phase / first treatment period main phase . Subjects personal family history long QT ( time interval begin Q wave end T wave ) syndrome hypokalemia . Previous history fainting , collapse , syncope , orthostatic hypotension , vasovagal reaction . Previous exposure study medication within 3 month prior screen . Any immunosuppressive treatment within 6 week 5 halflives drug , whichever longer , study drug administration . Treatment another investigational drug within 3 month 10 halflives drug , whichever longer , prior screen participation 4 investigational drug study within 1 year prior screen . History clinical evidence alcoholism drug abuse within 3year period prior screen . Excessive caffeine consumption , define ≥ 800 mg ( 7 cup coffee 14 cup tea ) per day screening . Smoking within last 3 month prior screen inability refrain smoke course study . Treatment prescribed medication ( include vaccine ) overthecounter ( OTC ) medication ( include herbal medicine ) within 2 week prior screen . Loss 250 mL blood within 3 month prior screen . Lymphopenia ( &lt; 1000 cells/μL ) screen Day −1 pilot phase / first treatment period main phase . Viral , fungal ( exception onychomycosis dermatomycosis ) , bacterial , protozoal infection within 4 week first study drug administration . Positive result hepatitis serology , except vaccinated subject subject past resolve hepatitis , screen . Positive result human immunodeficiency virus ( HIV ) serology screen . Any circumstance condition , , opinion investigator , may affect full participation study compliance protocol . Legal incapacity limit legal capacity screening .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Ponesimod</keyword>
	<keyword>Bioavailability</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Safety</keyword>
</DOC>